JPMorgan raised the firm’s price target on Guardant Health (GH) to $70 from $60 and keeps an Overweight rating on the shares following the analyst day. The company updated its 2028 financial targets, now calling for $2.2B in 2028 revenue versus the over $2.0B target given during the 2023 analyst day, the analyst tells investors in a research note. JPMorgan says this translates to a 34% annual growth through 2028.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $80 from $70 at UBS
- Guardant Health’s Strategic Advancements and Growth Potential Earns Buy Rating
- Guardant Health Hosts Investor Day in NYC
- Guardant Health, Quest Diagnostics announce blood-based screening test pact
- Guardant Health: Buy Rating Backed by Growth Potential and Innovation in Cancer Screening